# Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer

Clinical trial · The Methodist Hospital Research Institute

- Archive id: nct:NCT07820358
- Published: 2026-09-15
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07820358
- Source URL: https://clinicaltrials.gov/study/NCT07820358
- Provenance: clinicaltrials

## Abstract

The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1 endometrioid endometrial cancer while preserving fertility in women of reproductive age with endometrial atypical hyperplasia (EAH) or FIGO grade 1 endometrioid endometrial cancer who wish to preserve their fertility. The main questions it aims to answer are: \* What proportion of participants achieve a complete pathological response after treatment? \* How durable is the response at 12 months? \* What effect does the treatment have on metabolic outcomes (weight, BMI, HbA1c) and quality of life? Participants will: \* Receive an LNG-IUD \* Receive semaglutide 2.4mg \* Participate in a structured weight loss program \* Undergo hysteroscopy with endometrial sampling to assess treatment response \* Complete quality-of-life assessments at baseline, 6 months, and 12 months

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: SWIFT
- status: NOT_YET_RECRUITING
- phase: PHASE2
- study type: INTERVENTIONAL
- enrollment: 48
- sponsor: The Methodist Hospital Research Institute
- conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight
- interventions: DRUG: Semaglutide (Wegovy) weekly injection; DEVICE: LNG-IUD (Progestin); BEHAVIORAL: Structured Weight Loss Program
- start date: 2027-01-01
- start date type: ESTIMATED
- primary completion date: 2028-12-31
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.